5 best RTSM platforms for Phase II clinical trials in 2026

A dose-escalation cohort that closes and a new efficacy arm that opens shouldn't cost you a change order and a two-week wait from your randomization vendor. Randomization and trial supply management (RTSM) software that can't keep pace with a protocol still finding its shape turns routine Phase II adjustments into scheduling dependencies you didn't budget for. Viedoc's RTSM software handles static and dynamic randomization, kit allocation, and resupply forecasting from inside the same eClinical platform your site staff already use. This comparison evaluates five RTSM platforms for Phase II trials across randomization flexibility, EDC integration, amendment speed, and compliance credentials.

You're likely running a multi-arm or adaptive design where enrollment pace and evolving dosing decisions pull against a fixed system architecture. Your team needs to make changes as the science develops, not wait on a configuration queue every time the protocol committee meets. Your supply chain still has to work too, forecasting wastage and resupply against a patient population whose size isn't always predictable this early.

Enterprise RTSM built for large Phase III programs often carries configuration overhead and change processes that suit a locked protocol, but slow you down while yours is still evolving. Standalone IWRS systems that sit apart from your EDC create a second login and a reconciliation problem between two databases. A Phase II study needs a system that's fast to stand up, easy to amend without a formal change order, and built as one system with your data capture, not alongside it.

Best RTSM solutions: quick comparison

These five RTSM solutions represent the most evaluated options for Phase II clinical trials, reviewed across randomization flexibility, EDC integration, amendment speed, and compliance depth.

1. Viedoc

Viedoc's RTSM software is a randomization and supply management module built directly into Viedoc's EDC software, so your team randomizes, allocates kits, and reviews electronic case report form (eCRF) data in one interface rather than reconciling two systems. In a Phase 2a trial run by CTC and Dicot Pharma, the team introduced dynamic randomization for the first time across five sites in two countries, with the eCRF built and validated in just a few weeks and diary compliance exceeding 90 percent.

That integration matters most when the protocol amends mid-study. Randomization, kit allocation, and eCRF logic live in the same no-code Designer, so your team configures changes in-house rather than routing them through a vendor programmer for every cohort addition. Self-service builds go live in as little as one day, with full-service builds typically completed in 8 to 12 weeks, averaging 10.

Viedoc is ISO 27001 and SOC 2 certified, hosted on Microsoft Azure, and compliant with FDA 21 CFR Part 11, ICH GCP, GDPR, and EU Annex 11. The Viedoc Inspection Readiness Packet (VIRP) gives QA teams structured audit documentation ahead of a regulatory inspection, and 24/7 customer success support covers study teams working across time zones.

"Data handling, reviews, UAT, query management and the monitoring is a walk in the park, which makes it stand out from other EDCs... Unblinded randomisation, data import, ePRO, Alerts, RTSM, Logistics."

• Study scale: 8,000-plus studies run on Viedoc across 75-plus countries

• Build speed: Self-service builds live in as little as one day; full-service builds average 10 weeks

• Compliance: FDA 21 CFR Part 11, ICH GCP, GDPR, EU Annex 11; ISO 27001 and SOC 2 certified

• Inspection readiness: Viedoc Inspection Readiness Packet (VIRP) available to all customers

• Support: 24/7 customer success support across global offices

• No-code designer: Randomization and eCRF logic configured in-house, no vendor programmer required

2. Medidata

Medidata offers Rave RTSM as part of the Medidata Rave Clinical Cloud, a randomization and trial supply management system built to work as a single, unified environment with Rave EDC rather than a separate integration point. The platform supports simple to highly complex randomization and supply strategies, including multi-cohort management and dosing design across clinical and medical device trials. Its Edit Live Design capability lets study teams apply protocol updates, such as removing a treatment arm or adjusting a cohort, without stopping enrollment or issuing a formal change order. Medidata reports that unifying Rave RTSM with Rave EDC reduces the median time from last patient last visit to database lock compared with EDC-only studies, based on its own study-level data.

3. Suvoda

Suvoda provides RTSM, also referred to as IRT, built on a patented virtual partition architecture that separates trial-specific customizations from the core product code. Suvoda's platform is purpose-built for complex protocols in oncology, CNS, and rare disease, supporting dynamic cohort and dose management, adaptive replacement and randomization, and direct-to-patient drug shipping. Its newer agentic RTSM approach uses AI agents to handle study configuration, customization, and testing, with the company reporting kickoff-to-user-acceptance-testing timelines as short as two weeks in preliminary testing. An embedded AI assistant, Sofia, is designed to surface depot inventory summaries and compliance views without building a report from scratch.

4. Signant Health

Signant Health offers SmartSignals RTSM, a randomization and trial supply management solution built around configurable design checklists intended to reduce duplicative design calls during study setup. The platform is designed to handle complex randomization schemes and dosing schedules, with the same iterative design process applied to protocol amendments during the study. Signant's RTSM supports direct-to-patient supply distribution, securely managing patient shipping addresses for decentralized and hybrid trial models, and integrates with the company's eCOA and clinical supply management tools. The platform includes free picking functionality, which allows supply requests by quantity rather than specific kit numbers to reduce overage.

5. Almac Clinical Technologies

Almac Clinical Technologies provides IXRS3, an interactive response technology platform built to handle patient randomization and trial supply management across every study phase. The platform supports simple to complex adaptive designs with real-time allocation methods intended to maintain balanced treatment assignments and study blinding. IXRS3 offers two startup modes with differing levels of customization, speed to go-live, and cost, along with pre-built integrations for eCOA, EDC, and single sign-on partners. Almac backs the platform with 24/7 in-house technical support from biostatisticians, language specialists, and system integration professionals, and reports the system ran on more than 4,500 sites in 2025.

What to look for in RTSM solutions for Phase II clinical trials

Randomization design flexibility for evolving protocols

A Phase II protocol rarely stays static from first patient in to last patient out. Cohort expansions, dose modifications, and adaptive design elements all require a randomization engine that can absorb changes without a full system rebuild.

Best-in-class RTSM handles static and dynamic randomization, multiple concurrent schemes within a single study, and cross-over or re-treatment designs, all configurable by your own team rather than a vendor's build queue. A platform that can only handle the randomization scheme defined at study start forces you to either simplify your design or accept delays every time it evolves.

Integration between RTSM and the EDC

Randomization events, kit dispensation, and eCRF data all describe the same patient visit, and a standalone RTSM system that doesn't share a database with your EDC creates a reconciliation task that didn't need to exist. Every separate login is also a separate place for a data discrepancy to hide.

The strongest setups run randomization and eCRF data capture on one platform, with a single audit trail and no manual export-and-match step between systems. That single-database model is what makes site training faster too, since your staff learn one interface instead of two.

Mid-study amendment turnaround

Interim data reads in Phase II often trigger protocol amendments, and every day spent waiting on a formal RTSM change order is a day your enrollment timeline slips. The gap between a platform that supports self-service amendments and one that routes every change through a vendor programmer compounds across a multi-arm study.

Look for a system where in-house teams can update randomization ratios, add a cohort, or adjust dosing logic directly, with the vendor's support team available for validation rather than gatekeeping every edit. A slow amendment process on a fast-moving Phase II design creates real enrollment risk, not just an administrative delay.

Supply chain forecasting and waste reduction

Phase II enrollment projections shift more than Phase III projections do, which makes drug supply forecasting harder to get right and more expensive to get wrong. An RTSM system with weak resupply automation either over-orders investigational product or leaves sites waiting on stock.

Real-time inventory visibility, automated resupply alerts tied to site-specific thresholds, and expiration tracking all reduce both waste and stockout risk. This matters even more for expensive biologics or cell and gene therapy products, where overage carries a direct cost.

How to choose the right RTSM solution for Phase II clinical trials

Step 1: Define how much your protocol is likely to change

Before comparing vendors, assess how volatile your Phase II design actually is. A single-arm, fixed-dose study has different RTSM requirements than an adaptive, multi-cohort design where the randomization scheme itself may shift after an interim analysis.

Step 2: Assess whether a standalone RTSM or an EDC-embedded model fits your team

Decide whether your data management team wants one platform for randomization and data capture, or is comfortable managing the reconciliation between two separate systems. This decision affects training time, audit trail complexity, and how quickly your team can act on discrepancies.

Step 3: Evaluate each vendor's mid-study amendment process directly

Ask each vendor, in concrete terms, what happens when your protocol changes after go-live. Check whether your CRO partner has direct experience with the vendor's amendment turnaround on a comparable study, since a vendor's marketing claims and its actual mid-study performance can differ.

Step 4: Scrutinize supply forecasting depth for your specific drug product

If you're managing a temperature-sensitive biologic, a controlled substance, or a product with a tight expiration window, confirm the platform's resupply automation and cold-chain integration match your actual logistics, not just its general feature list.

Step 5: Choose a platform built for how Phase II actually runs

Once you've mapped your protocol's likely evolution against each platform's amendment process and supply depth, choose the system that lets your team act on interim data without a vendor bottleneck. Viedoc's RTSM software is designed for exactly that kind of Phase II agility, and you can book a demo to see how it handles your specific protocol.

Frequently asked questions

What is the best RTSM platform for Phase II clinical trials?

Viedoc is the best RTSM choice for Phase II clinical trials, since its randomization and supply management module runs inside the same EDC platform your team already uses, with self-service builds live in as little as one day and full-service builds averaging 10 weeks. Medidata is a strong alternative for sponsors already standardized on Rave EDC and running larger, more complex Phase II programs. Suvoda is worth considering for oncology or rare disease protocols with heavy adaptive design requirements, given its purpose-built architecture for that complexity.

What should I look for when choosing an RTSM platform for a Phase II trial?

Prioritize randomization flexibility for a protocol that may still change, tight integration with your EDC so randomization and clinical data share one audit trail, and a mid-study amendment process your own team can drive rather than one that depends on a vendor's build queue. Supply chain forecasting depth also matters, particularly for expensive or temperature-sensitive investigational products.

How long does it take to build and deploy RTSM for a Phase II study?

This varies by vendor and by whether you're self-building or using full-service support. With Viedoc, self-service study builds can go live in as little as one day, while full-service builds typically take 8 to 12 weeks, averaging 10. Vendors offering an embedded, no-code configuration model generally move faster than those requiring a dedicated build team for every study.

How does Viedoc's RTSM compare to Medidata's Rave RTSM for Phase II trials?

Both platforms unify randomization with EDC data capture rather than treating RTSM as a bolt-on system. Viedoc's no-code Designer lets your own data management team configure and amend randomization logic directly, while Medidata's Edit Live Design applies protocol updates without downtime through its own configuration process. Medidata's broader footprint in large, complex Phase III programs makes it a familiar choice for sponsors who will eventually scale that direction, while Viedoc is built around the speed and self-sufficiency that Phase I and Phase II studies need.

What is the difference between RTSM and a standalone IWRS or IVRS system?

RTSM is the current industry term for the same category of technology that older IWRS (Interactive Web Response System) and IVRS (Interactive Voice Response System) platforms provided: patient randomization and drug supply management. Modern RTSM systems have expanded beyond the phone- and web-based interfaces of legacy IWRS and IVRS to include real-time inventory visibility, direct-to-patient shipping, and, in some cases, direct integration with the EDC platform capturing clinical data.

Can RTSM support adaptive Phase II designs with mid-study dose or cohort changes?

Yes, modern RTSM platforms are built to handle adaptive designs, including cohort expansions, dose modifications, and multiple concurrent randomization schemes within a single study. The degree of self-service control varies by vendor. Some require a formal change order and vendor-side configuration for every amendment, while others, including Viedoc, let your in-house team make these updates directly.

Making the right RTSM choice for Phase II clinical trials

The RTSM market spans embedded modules built into a broader eClinical suite and standalone platforms designed to plug into whichever EDC a sponsor has already chosen, with the global eClinical software market estimated at over $11 billion in 2025 and growing at roughly 14 percent annually. Both approaches can support a Phase II trial competently, but they shift where the reconciliation work and the change-order dependency sit.

Match your choice to your organization's actual profile: study complexity, whether your team wants direct control over amendments, and whether your existing EDC vendor already offers a unified RTSM module. US sponsors often weight speed to first patient in and total cost of ownership most heavily, while EMEA and APAC sponsors typically weight compliance credential depth and vendor stability across their submission markets.

Whichever platform you choose, the switching cost of moving RTSM vendors mid-portfolio is real, and a slow amendment process compounds every time your protocol changes, not just once.

Why Viedoc is the best RTSM choice for Phase II clinical trials

If your Phase II protocol is still evolving, you need an RTSM system that moves at the same pace, not one that treats every cohort change as a formal request. Viedoc's randomization and trial supply management module runs inside the same EDC platform your site staff already use, with self-service builds live in as little as one day and full-service builds averaging 10 weeks, well inside the timelines a standalone RTSM change order typically requires.

That speed comes from the no-code Designer, which lets your data management team configure and amend randomization logic in-house, alongside unlimited user seats and transparent, study-based pricing with no per-user fees. Viedoc runs on Microsoft Azure, is ISO 27001 and SOC 2 certified, and complies with FDA 21 CFR Part 11, ICH GCP, GDPR, and EU Annex 11, with the Viedoc Inspection Readiness Packet giving your QA team structured documentation ahead of an inspection.

If you're evaluating RTSM for an evolving Phase II design, book a demo or request a proposal and our team will walk through your protocol's randomization and supply requirements directly.